[1]
|
McCrindle, B.W., Rowley, A.H., Newburger, J.W., Burns, J.C., Bolger, A.F., Gewitz, M., Baker, A.L., Jackson, M.A., Takahashi, M., Shah, P.B., Kobayashi, T., Wu, M.H., Saji, T.T., et al. (2017) Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals from the American Heart Association. Circulation, 135, e927-e999. https://doi.org/10.1161/CIR.0000000000000484
|
[2]
|
Burns, J.C. and Glodé, M.P. (2004) Kawasaki Syndrome. Lancet, 364, 533-544.
https://doi.org/10.1016/S0140-6736(04)16814-1
|
[3]
|
Burns, J.C. (2018) History of the Worldwide Emergence of Kawasaki Disease. International Journal of Rheumatic Diseases, 21, 13-15. https://doi.org/10.1111/1756-185X.13214
|
[4]
|
Takahashi, K., Oharaseki, T. and Yokouchi, Y. (2011) Pathogene-sis of Kawasaki Disease. Clinical and Experimental Immunology, 164, 20-22. https://doi.org/10.1111/j.1365-2249.2011.04361.x
|
[5]
|
Makino, N., Nakamura, Y., Yashiro, M., Sano, T., Ae, R., Kosami, K., Kojo, T., Aoyama, Y., Kotani, K. and Yanagawa, H. (2018) Epidemiological Observations of Kawasaki Disease in Japan, 2013-2014. Pediatrics International, 60, 581-587. https://doi.org/10.1111/ped.13544
|
[6]
|
Bayers, S., Shulman, S.T. and Paller, A.S. (2013) Kawasaki Disease: Part I. Diagnosis, Clinical Features, and Pathogenesis. Journal of the American Academy of Dermatology, 69, 501.e1-501.e11.
https://doi.org/10.1016/j.jaad.2013.07.002
|
[7]
|
Dimitriades, V.R., Brown, A.G. and Gedalia, A. (2014) Kawasaki Disease: Pathophysiology, Clinical Manifestations, and Management. Current Rheumatology Reports, 16, Article No. 423. https://doi.org/10.1007/s11926-014-0423-x
|
[8]
|
Kato, H., Koike, S. and Yokoyama, T. (1979) Kawasaki Disease: Effect of Treatment on Coronary Artery Involvement. Pediatrics, 63, 175-179. https://doi.org/10.1542/peds.63.2.175
|
[9]
|
Furusho, K., Sato, K., Soeda, T., et al. (1983) High-Dose Intravenous Gammaglobulin for Kawasaki Disease. Lancet, 322, 1359. https://doi.org/10.1016/S0140-6736(83)91109-1
|
[10]
|
Wright, D.A., Newburger, J.W., Baker, A. and Sundel, R.P. (1996) Treatment of Immune Globulin-Resistant Kawasaki Disease with Pulsed Doses of Corticosteroids. The Journal of Pediatrics, 128, 146-149.
https://doi.org/10.1016/S0022-3476(96)70447-X
|
[11]
|
Ogata, S., Bando, Y., Kimura, S., et al. (2009) The Strategy of Immune Globulin Resistant Kawasaki Disease: A Comparative Study of Additional Immune Globulin and Steroid Pulse Therapy. Journal of Cardiology, 53, 15-19.
https://doi.org/10.1016/j.jjcc.2008.08.002
|
[12]
|
Okada, K., Hara, J., Maki, I., Miki, K., Matsuzaki, K., Matsuoka, T., Yamamoto, T., Nishigaki, T., Kurotobi, S. and Sano, T. (2009) Osaka Kawasaki Disease Study Group. Pulse Methylprednisolone with Gammaglobulin as an Initial Treatment for Acute Kawasaki Disease. European Journal of Pe-diatrics, 168, 181-185.
https://doi.org/10.1007/s00431-008-0727-9
|
[13]
|
Ogata, S., Ogihara, Y., Honda, T., Kon, S., Akiyama, K. and Ishii, M. (2012) Corticosteroid Pulse Combination Therapy for Refractory Kawasaki Disease: A Randomized Trial. Pediatrics, 129, e17-e23.
https://doi.org/10.1542/peds.2011-0148
|
[14]
|
Tremoulet, A.H., Jain, S., Jaggi, P., Jimenez-Fernandez, S., Pancheri, J.M., Sun, X., Kanegaye, J.T., Kovalchin, J.P., Printz, B.F., Ramilo, O. and Burns, J.C. (2014) Infliximab for Intensifi-cation of Primary Therapy for Kawasaki Disease: A Phase 3 Randomised, Double-Blind, Placebo-Controlled Trial. Lan-cet, 383, 1731-1738.
https://doi.org/10.1016/S0140-6736(13)62298-9
|
[15]
|
Bayers, S., Shulman, S.T. and Paller, A.S. (2013) Kawasaki Disease: part II. Complications and Treatment. Journal of the American Academy of Dermatology, 69, 513.e1-513.e8. https://doi.org/10.1016/j.jaad.2013.06.040
|
[16]
|
Shimizu, C., Kim, J., Stepanowsky, P., Trinh, C., Lau, H.D., Akers, J.C., Chen, C., Kanegaye, J.T., Tremoulet, A., Ohno- Machado, L. and Burns, J.C. (2013) Differential Expression of miR-145 in Children with Kawasaki Disease. PLOS ONE, 8, e58159. https://doi.org/10.1371/journal.pone.0058159
|
[17]
|
Ma, J., Gui, H., Tang, Y., Ding, Y., Qian, G., Yang, M., Wang, M., Song, X. and Lv, H. (2021) In Silico Identification of 10 Hub Genes and an miRNA-mRNA Regulatory Network in Acute Kawasaki Disease. Frontiers in Genetics, 12, Article 585058. https://doi.org/10.3389/fgene.2021.585058
|
[18]
|
Chu, M., Wu, R., Qin, S., Hua, W., Shan, Z., Rong, X., Zeng, J., Hong, L., Sun, Y., Liu, Y., Li, W., Wang, S. and Zhang, C. (2017) Bone Marrow-Derived MicroRNA-223 Works as an Endocrine Genetic Signal in Vascular Endothelial Cells and Participates in Vascular Injury from Kawasaki Disease. Journal of the American Heart Association, 6, e004878. https://doi.org/10.1161/JAHA.116.004878
|
[19]
|
Che, D., Li, J., Fu, L., Pi, L., Rong, X., Wang, Y., Xu, Y., Huang, P., Chu, M. and Gu, X. (2018) The rs1625579 T>G Poly-morphism in the miRNA-13 Gene Confers a Risk of Early-Onset Kawasaki Disease in a Southern Chinese Population. Infection and Drug Resistance, 11, 1055-1060. https://doi.org/10.2147/IDR.S174140
|